Cardiosense, Inc., a Chicago-based digital health company that uses artificial intelligence and multi-sensor devices to detect cardiovascular disease early, announced today that it has raised $15.1 million in Series A funding led by Broadview Ventures and Hatteras Venture Partners, with participation from Laerdal Million Lives Fund, OSF Ventures, UnityPoint Health Ventures, and Portal Innovations. The funds will be used to support team expansion, speed product development, and fund a large heart failure study.
Cardiosense is building a physiological waveform AI platform to develop predictive biomarkers to detect and manage cardiac disease. The Company has developed a suite of novel digital tools, multi-sensor devices, and analysis algorithms to detect early signs of cardiovascular disease, inform personalized therapy, and improve patient outcomes.
Cardiosense’s founding team has been working on the underlying technologies for over a decade, and the company plans to seek regulatory approval for its clinical-grade, multi-parameter wearable gadget, CardioTag, next year. In addition, the company is developing a sophisticated AI platform that analyzes raw physiological information to create digital biomarkers that may be used to identify at-risk patients and enable guided, individualized therapy.